Crystal structure of a prostate kallikrein isolated from stallion seminal plasma: a homologue of human PSA.

Prostate-specific kallikrein, a member of the gene family of serine proteases, was initially discovered in semen and is the most useful serum marker for prostate cancer diagnosis and prognosis. We report the crystal structure at 1.42A resolution of horse prostate kallikrein (HPK). This is the first structure of a serine protease purified from seminal plasma. HPK shares extensive sequence homology with human prostate-specific antigen (PSA), including a predicted chymotrypsin-like specificity, as suggested by the presence of a serine residue at position S1 of the specificity pocket. In contrast to other kallikreins, HPK shows a structurally distinct specificity pocket. Its entrance is blocked by the kallikrein loop, suggesting a possible protective or substrate-selective role for this loop. The HPK structure seems to be in an inactivated state and further processing might be required to allow the binding of substrate molecules. Crystal soaking experiments revealed a binding site for Zn(2+) and Hg(2+), two known PSA inhibitors.

[1]  B. Gibbs,et al.  Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. , 1997, Biochemistry.

[2]  D. Chan,et al.  Concentration of enzymatically active prostate‐specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models , 2001, The Prostate.

[3]  R. Freidinger,et al.  A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo , 2000, Nature Medicine.

[4]  P. Cuasnicú,et al.  Potential contraceptive use of epididymal proteins: immunization of male rats with epididymal protein DE inhibits sperm fusion ability. , 1998, Biology of reproduction.

[5]  M. Maruyama,et al.  Prostate‐specific antigen activates single‐chain urokinase‐type plasminogen activator , 1995, International journal of cancer.

[6]  G. Bricogne,et al.  [27] Maximum-likelihood heavy-atom parameter refinement for multiple isomorphous replacement and multiwavelength anomalous diffraction methods. , 1997, Methods in enzymology.

[7]  U. Stenman,et al.  Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. , 1999, Clinical chemistry.

[8]  D. Timm The crystal structure of the mouse glandular kallikrein‐13 (prorenin converting enzyme) , 1997, Protein science : a publication of the Protein Society.

[9]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[10]  D. Corey,et al.  Substrate specificity of prostate-specific antigen (PSA). , 1998, Chemistry & biology.

[11]  M. James,et al.  Rat submaxillary gland serine protease, tonin. Structure solution and refinement at 1.8 A resolution. , 1987, Journal of molecular biology.

[12]  A. Tulinsky,et al.  The refinement and the structure of the dimer of alpha-chymotrypsin at 1.67-A resolution. , 1985, The Journal of biological chemistry.

[13]  R M Esnouf,et al.  Further additions to MolScript version 1.4, including reading and contouring of electron-density maps. , 1999, Acta crystallographica. Section D, Biological crystallography.

[14]  H. Lilja,et al.  Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. , 1996, Urology.

[15]  Robert M. Stroud,et al.  Design of potent selective zinc-mediated serine protease inhibitors , 1998, Nature.

[16]  G J Barton,et al.  ALSCRIPT: a tool to format multiple sequence alignments. , 1993, Protein engineering.

[17]  P. Vihko,et al.  Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate. , 1994, Annals of medicine.

[18]  M. Barry Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .

[19]  B Honig,et al.  Computer simulations of the diffusion of a substrate to an active site of an enzyme. , 1987, Science.

[20]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[21]  Eleftherios P. Diamandis,et al.  The New Human Kallikrein Gene Family: Implications in Carcinogenesis , 2000, Trends in Endocrinology & Metabolism.

[22]  Anastassis Perrakis,et al.  Automated protein model building combined with iterative structure refinement , 1999, Nature Structural Biology.

[23]  M. Pollak,et al.  Insulin-like Growth Factors and Prostate Cancer , 2001, Cancer and Metastasis Reviews.

[24]  L. Ashworth,et al.  Molecular Cloning of the Human Kallikrein 15 Gene (KLK15) , 2001, The Journal of Biological Chemistry.

[25]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[26]  Takanori Nakamura,et al.  The chymotrypsin‐like activity of human prostate‐specific antigen, γ‐seminoprotein , 1987 .

[27]  J L Sussman,et al.  Specific chemical and structural damage to proteins produced by synchrotron radiation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[29]  A. Tulinsky,et al.  Comparison of the independent solvent structures of dimeric alpha-chymotrypsin with themselves and with gamma-chymotrypsin. , 1985, The Journal of biological chemistry.

[30]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[31]  W. Bode,et al.  Refined 2 A X-ray crystal structure of porcine pancreatic kallikrein A, a specific trypsin-like serine proteinase. Crystallization, structure determination, crystallographic refinement, structure and its comparison with bovine trypsin. , 1983, Journal of molecular biology.

[32]  J. Calvete,et al.  Purification, crystallization and identification by X-ray analysis of a prostate kallikrein from horse seminal plasma. , 2001, Acta crystallographica. Section D, Biological crystallography.

[33]  R J Fletterick,et al.  X-ray structures of a designed binding site in trypsin show metal-dependent geometry. , 1996, Biochemistry.

[34]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[35]  M. Vihinen Modeling of prostate specific antigen and human glandular kallikrein structures. , 1994, Biochemical and biophysical research communications.

[36]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[37]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[38]  H. Lilja,et al.  Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. , 1989, The Journal of biological chemistry.

[39]  H. Bartunik,et al.  Crystal structure of bovine beta-trypsin at 1.5 A resolution in a crystal form with low molecular packing density. Active site geometry, ion pairs and solvent structure. , 1989, Journal of molecular biology.

[40]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[41]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[42]  B. Cooperman,et al.  Inhibition of prostate-specific antigen (PSA) by alpha(1)-antichymotrypsin: salt-dependent activation mediated by a conformational change. , 2002, Biochemistry.

[43]  M. Webber,et al.  Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  E. Diamandis Prostate-specific antigen: a cancer fighter and a valuable messenger? , 2000, Clinical chemistry.

[45]  T. Marti,et al.  Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. , 1987, European journal of biochemistry.

[46]  P. Kraulis A program to produce both detailed and schematic plots of protein structures , 1991 .

[47]  B. Katz,et al.  Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. , 2001, Journal of medicinal chemistry.

[48]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[49]  R. Wolfert,et al.  "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. , 2000, Urology.

[50]  M. Raida,et al.  Biochemical and conformational characterisation of HSP‐3, a stallion seminal plasma protein of the cysteine‐rich secretory protein (CRISP) family , 1997, FEBS letters.

[51]  E. Getzoff,et al.  A structural model for the prostate disease marker, human prostate‐specific antigen , 1994, Protein science : a publication of the Protein Society.

[52]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[53]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[54]  E. Diamandis Sequencing with microarray technology--a powerful new tool for molecular diagnostics. , 2000, Clinical chemistry.